zoledronsav xellia 4 mg/5 ml koncentrátum oldatos infúzióhoz
xellia pharmaceuticals aps - zoledronsav -
ranivisio
midas pharma gmbh - ranibizumabbal - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - szemészeti - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
nitrofurantoin-q pharma 100 mg kemény kapszula
q pharma kft. - nitrofurantoin -
atazanavir alvogen 200 mg kemény kapszula
alvogen pharma trading europe eood - atazanavir -
atazanavir alvogen 300 mg kemény kapszula
alvogen pharma trading europe eood - atazanavir -
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrél-bezilát - peripheral vascular diseases; stroke; myocardial infarction - antitrombotikus szerek - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-szegmenst nem mutató akut miokardiális infarktus, kombinálva asa orvosilag kezelt betegek jogosult a thrombolyticus terápia. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. további információkért lásd az 5.
ramipril q pharma 1,25 mg tabletta
q pharma kft. - a ramipril -
ramipril q pharma 2,5 mg tabletta
q pharma kft. - a ramipril -
ramipril q pharma 5 mg tabletta
q pharma kft. - a ramipril -
ramipril q pharma 10 mg tabletta
q pharma kft. - a ramipril -